Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals

HIV Medicine

Volumn 15, Issue 8, 2014, Pages 449-457

  Zoufaly, A ^a   Kiepe, J G ^a   Hertling, S ^a   Hufner A ^a   Degen, O ^a   Feldt, T ^b   Schmiedel, S ^a   Kurowski, M ^c   van Lunzen, J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Auguste Viktoria Klinikum   (Germany)

Author keywords

HIV infection; HIV viraemia; Immune activation; Viral blips

Indexed keywords

ATAZANAVIR; C REACTIVE PROTEIN; CD16 ANTIGEN; CD19 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; EFAVIRENZ; EMTRICITABINE; HLA DR ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ANTIRETROVIRUS AGENT; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTPATIENT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRAL BLIP; VIRUS INFECTION; AGED; CHEMISTRY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PATHOLOGY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 84906327440     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12134     Document Type: Article

References (32)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299.
2. Garcia-Gasco P, Maida I, Blanco F etal. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61: 699-704.
3. Maldarelli F, Palmer S, King MS etal. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3: e46.
4. Nettles RE. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-829.
5. Garrett NJ, Apea V, Nori A etal. Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management. J Clin Virol 2012; 53: 354-355.
6. Gatanaga H, Tsukada K, Honda H etal. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis 2009; 48: 260-262.
7. Manavi K. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin Trials 2008; 9: 283-286.
8. Ostrowski MA, Krakauer DC, Li Y etal. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 1998; 72: 7772-7784.
9. Easterbrook PJ, Ives N, Waters A etal. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/mL. AIDS 2002; 16: 1521-1527.
10. Hazenberg MD, Otto SA, van Benthem BH etal. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881-1888.
11. Brenchley JM, Price DA, Schacker TW etal. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
12. Marchetti G, Cozzi-Lepri A, Merlini E etal. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011; 25: 1385-1394.
13. Lee PK. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006; 57: 803-805.
14. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008; 122: 22-28.
15. Tobin NH, Learn GH, Holte SE etal. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79: 9625-9634.
16. Kieffer TL, Finucane MM, Nettles RE etal. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189: 1452-1465.
17. Gutierrez C, Diaz L, Vallejo A etal. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE 2011; 6: e27864.
18. Hatano H, Delwart EL, Norris PJ etal. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010; 24: 2535-2539.
19. Chomont N, El-Far M, Ancuta P etal. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900.
20. Chun TW, Justement JS, Pandya P etal. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185: 1672-1676.
21. Strain MC, Little SJ, Daar ES etal. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191: 1410-1418.
22. Buzon MJ, Massanella M, Llibre JM etal. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
23. Podsadecki Thomas J, Vrijens Bernard C, Tousset Eric P, Rode Richard A, Hanna George J. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196: 1773-1778.
24. Cohen Stuart JW, Hazebergh MD, Hamann D etal. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000; 25: 203-211.
25. Grennan JT, Loutfy MR, Su D etal. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205: 1230-1238.
26. Kaplan RC, Sinclair E, Landay AL etal. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203: 452-463.
27. Kalayjian RC, Machekano RN, Rizk N etal. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201: 1796-1805.
28. Hunt PW, Cao HL, Muzoora C etal. Impact of CD8+ T cell activation on CD4+ T cell recovery and mortality in HIV-infected ugandans initiating antiretroviral therapy. AIDS 2011; 25: 2123-2131.
29. Hunt PW, Martin JN, Sinclair E etal. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
30. Taiwo B, Hunt PW, Gandhi RT etal. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr 2013; 63: 101-104.
31. Serrano-Villar S, Gutierrez C, Vallejo A etal. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 2013; 66: 57-66.
32. Taiwo BHP, Gandhi R, Ellingson A, McKenna M, Jacobson J, Grips B. Immune activation in HIV-1 patients experiencing transiently detectable viremia during antiretroviral treatment. Conference on retroviruses and opportunistic infections. Seattle, USA, 2012.